<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081012</url>
  </required_header>
  <id_info>
    <org_study_id>191110</org_study_id>
    <nct_id>NCT04081012</nct_id>
  </id_info>
  <brief_title>N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Chronic Thromboembolic Pulmonary Hypertension.</brief_title>
  <acronym>NAC-PostRep</acronym>
  <official_title>N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Patients With Chronic Thromboembolic Pulmonary Hypertension Undergoing Pulmonary Balloon Angioplasty and Pulmonary Endarterectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cardiologia Ignacio Chavez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cardiologia Ignacio Chavez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the use of N-acetyl cysteine in post-reperfusion pulmonary injury in
      patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary balloon
      angioplasty and pulmonary endarterectomy. Half of the patients will receive N-acetyl cysteine
      and the other placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For chronic pulmonary embolism thrombus hypertension, the potentially curative treatment is
      endarterectomy, however in 12 to 60% it does not present surgical susceptibility, so
      pulmonary balloon angioplasty is the secondary option. In these procedures the complication
      that occurs most frequently is pulmonary oedema after reperfusion is a frequent complication
      (17.8-65%), appears between 24-72 hours after the intervention and the diagnosis is made in
      the presence of infiltrate interstitial in chest radiography or computed tomography of the
      chest. Initially it was believed that it was difficult due to the increase in perfusion of
      secondary flow in the territory due to pulmonary vascular dilation, it is now believed that
      microtraumatism is involved by the guides and balloon used, vascular dysfunction and
      cytokines and innate immunity and adaptive, complement activation, coagulation cascade
      activation, apoptosis pathway activation, endothelial dysfunction caused by reperfusion
      contribute to cell dysfunction.

      The use of N-acetyl cysteine for its antioxidant properties, inflammatory response
      attenuator, reduction of reactive oxygen species (ROS) and that in addition to having already
      had to reduce the condition of decrease in post-reperfusion ischemia15,16 in other situations
      is a viable option in the treatment of acute post-reperfusion edema in patients sometimes a
      pulmonary endarterectomy and balloon pulmonary angioplasty.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">May 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind clinical trial of the treatment will be the treating physician and radiologist, of parallel groups in patients undergoing EAP and BPA.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>It will be through sealed, opaque and numbered envelopes sequentially. The assignment sequence will be done by the pharmacist, the principal investigator will recruit the patients. Researchers and site staff (with the exception of the investigating pharmacologist) will be blinded to the assigned treatment. There will be no circumstances to unmask and reveal the intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Post-reperfusion pulmonary injury.</measure>
    <time_frame>72 hours</time_frame>
    <description>Chest tomography will be performed using 35 mA, 100 Kv and 6 mm cuts, then the simple thorax (low dose) holding the inspiration in the cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, pitch of 1 and cuts 1 mm Multiplanar reconstructions with Kernel filters B26f, B50f and B70f for mediastinum and lung respectively, at 1 mm cuts. And anteroposterior chest radiographs will be obtained with the same equipment, at the beginning of the study and daily on days 1 to 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of cytokines (pg/ml)</measure>
    <time_frame>Basal and at 72 hours</time_frame>
    <description>Blood samples for the determination of plasma cytokines will be extracted from the peripheral venous puncture, jugular venous line and / or Swan Ganz catheter in patients undergoing EAP or by pigtail pulmonary artery trunk catheter to patients who are underwent BPA, at the following time points: baseline upon admission to hospital and / or after induction of anesthesia and before the incision (T1), and at 72 hours (T2) after the onset of surgery. All blood samples will receive the same process. immunohistochemistry will be performed for IP-10 (1: 250, ab9807; Abcam, Cambridge, UK), IL-8 (1: 100; ab7747; Abcam), MCP-1 (1: 100, ab73680; Abcam) and IL-6 (1: 100, ab6672; Abcam) will be performed with a 3,39-diaminobenzidine peroxidase substrate from R&amp;D kit Systems (Minneapolis, MN, USA). Specifically for IP-10, IL-8, RANTES, MIG and MCP-1 will be measured by Human Chemokine Kit Cytometric Bead Array (Becton Dickinson, Franklin Lakes, NJ, USA), following the manufacturer's specifications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentaje of Complications (%)</measure>
    <time_frame>30 days</time_frame>
    <description>Dead</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>N-acetyl Cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before endarterectomy or balloon angioplasty.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals. All study medications will be prepared by the Pharmacology department, which is not involved in patient care; the name of the medication and dose of the original ampule will be erased and also an identification label will be placed with the name, registration number, bed number, date and will be indifferent for groups with the same type of ampoule, with the same type of labeling</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <description>Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.</description>
    <arm_group_label>N-acetyl Cysteine</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients who are diagnosed with group 4 pulmonary hypertension and are susceptible to
        pulmonary endarterectomy or balloon angioplasty in patients over 18 years.

        Exclusion Criteria:

          -  Patients who do not accept admission to the trial.

          -  Presence of arterial hypotension or sepsis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Elena Soto Lopez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cardiología &quot;Ignacio Chávez&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Elena Soto Lopez, Dr.</last_name>
    <phone>5538808997</phone>
    <email>mesoto50@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huitzilihuitl Saucedo Orozco, Dr.</last_name>
    <phone>4921373556</phone>
    <email>huitzilihuitls@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional Ignacio Chavez</name>
      <address>
        <city>Ciudad de mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huitzilihuitl Saucedo Orozco, Dr.</last_name>
      <phone>4921373556</phone>
      <email>huitzilihuitls@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Elena Soto López, Dr.</last_name>
      <phone>5538880897</phone>
      <email>mesoto50@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of Pulmonary Embolism: An Update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90. doi: 10.1016/j.jacc.2015.11.061. Review.</citation>
    <PMID>26916489</PMID>
  </reference>
  <reference>
    <citation>Huisman MV, Barco S, Cannegieter SC, Le Gal G, Konstantinides SV, Reitsma PH, Rodger M, Vonk Noordegraaf A, Klok FA. Pulmonary embolism. Nat Rev Dis Primers. 2018 May 17;4:18028. doi: 10.1038/nrdp.2018.28. Review.</citation>
    <PMID>29770793</PMID>
  </reference>
  <reference>
    <citation>Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 May 27;350(22):2257-64.</citation>
    <PMID>15163775</PMID>
  </reference>
  <reference>
    <citation>Ogawa A, Satoh T, Fukuda T, Sugimura K, Fukumoto Y, Emoto N, Yamada N, Yao A, Ando M, Ogino H, Tanabe N, Tsujino I, Hanaoka M, Minatoya K, Ito H, Matsubara H. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of a Multicenter Registry. Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11). pii: e004029. doi: 10.1161/CIRCOUTCOMES.117.004029.</citation>
    <PMID>29101270</PMID>
  </reference>
  <reference>
    <citation>Wilkens H, Lang I, Behr J, Berghaus T, Grohe C, Guth S, Hoeper MM, Kramm T, Krüger U, Langer F, Rosenkranz S, Schäfers HJ, Schmidt M, Seyfarth HJ, Wahlers T, Worth H, Mayer E. Chronic thromboembolic pulmonary hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol. 2011 Dec;154 Suppl 1:S54-60. doi: 10.1016/S0167-5273(11)70493-4.</citation>
    <PMID>22221974</PMID>
  </reference>
  <reference>
    <citation>Laubach VE, Sharma AK. Mechanisms of lung ischemia-reperfusion injury. Curr Opin Organ Transplant. 2016 Jun;21(3):246-52. doi: 10.1097/MOT.0000000000000304. Review.</citation>
    <PMID>26945320</PMID>
  </reference>
  <reference>
    <citation>Zabini D, Heinemann A, Foris V, Nagaraj C, Nierlich P, Bálint Z, Kwapiszewska G, Lang IM, Klepetko W, Olschewski H, Olschewski A. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2014 Oct;44(4):951-62. doi: 10.1183/09031936.00145013. Epub 2014 Jul 17.</citation>
    <PMID>25034560</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Pu LY, Lu L, Wang XH, Zhang F, Rao JH. N-acetylcysteine attenuates reactive-oxygen-species-mediated endoplasmic reticulum stress during liver ischemia-reperfusion injury. World J Gastroenterol. 2014 Nov 7;20(41):15289-98. doi: 10.3748/wjg.v20.i41.15289.</citation>
    <PMID>25386077</PMID>
  </reference>
  <reference>
    <citation>Geudens N, Wuyts WA, Rega FR, Vanaudenaerde BM, Neyrinck AP, Verleden GM, Lerut TE, Van Raemdonck DE. N-acetyl cysteine attenuates the inflammatory response in warm ischemic pig lungs. J Surg Res. 2008 May 15;146(2):177-83. Epub 2007 Jul 20.</citation>
    <PMID>17644109</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cardiologia Ignacio Chavez</investigator_affiliation>
    <investigator_full_name>Maria Elena Soto, MsC and PhD</investigator_full_name>
    <investigator_title>Clinical Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within 8 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access request will be reviewed by an internal review panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

